Neurophet, a brain imaging company, recently secured 32 billion won ($21.5 million) in institutional investment, according to KBR. This capital injection fuels a neuroimaging sector valued at USD 37.63 billion in 2023, projected to surpass USD 56.58 billion by 2030, according to biospace. Significant expansion in medical diagnostics and research is signaled by such growth.
The neuroimaging market is undeniably expanding at a rapid pace, but leading research firms present vastly different current valuations and future projections for its size. An opaque landscape for strategic planning is created by this discrepancy, despite the clear influx of capital.
While the overall growth trajectory for brain imaging technology is clear, stakeholders must carefully evaluate specific market segments and their respective growth drivers to navigate the diverse landscape of neuroimaging opportunities.
The Current Landscape of Neuroimaging Growth
The neuroimaging market is expected to grow at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2030, according to biospace. A robust sector is confirmed by this sustained expansion.
North America accounted for over 39% of revenue share in 2025, according to Precedence Research. Market penetration and adoption are heavily concentrated due to this regional dominance, indicating either significant barriers to entry elsewhere or substantial untapped potential in other geographies.
Brain Imaging Devices: A Specialized Growth Engine
The global brain imaging devices market is projected to grow from approximately USD 5 billion in 2024 to around USD 7.7 billion by 2032, with a compound annual growth rate of 5.50% to 6%, according to Research and Markets. Grand View Research projects a higher CAGR of 8.2% from 2025 to 2030 for this segment. While both sources confirm growth, the variance in CAGR highlights the difficulty in precisely forecasting even specific sub-segments.
